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1. Introduction
Integrins are a family of heterodimeric cell surface receptors
that mediate cell–extracellular matrix and cell–cell interac-
tions.[1] Integrin-mediated adhesion is critical in multiple
phases of development and maintenance of tissue physiology.
Conversely, aberrant integrin function that can arise because
of inappropriate levels of activation is implicated in many dis-
eases, including cancer, thrombosis, and immune system disor-
ders.[2] In particular, recent studies provide evidence of the im-
portance of pairs and wider combinations of RGD-binding in-
tegrins in angiogenesis and cancer, and suggest the develop-
ment of dual and multi-integrin antagonists to efficiently
target these processes.[3] Among tumor-associated integrins
from the RGD-binding subfamily, a5b1 along with aVb3 and
other aV integrins are highly expressed on a wide range of
tumors and surrounding vasculature, where they are correlated
with disease progression and poor prognosis. These integrins
recognize the RGD sequence in endogenous ligands (e.g. fibro-
nectin, vitronectin) across their extracellular a/b subunit inter-
face containing the metal-ion-dependent adhesion site
(MIDAS).[4] The context of the ligand RGD sequence (flanking
residues, three dimensional presentation) and different fea-
tures of the integrin binding pocket determine the recognition
specificity.[5]
The most used strategy to inhibit integrin function consists
of blocking endogenous ligand binding by small-molecule in-
tegrin antagonists designed around the epitope of the natural
ligands: the RGD motif. Unfortunately, linear RGD-containing
peptides suffer from low affinity and specificity, as one factor
that affects integrin affinity and specificity for RGD ligands is
a well-defined conformation of the ligand. This drawback has
been circumvented by the use of cyclic peptidic and peptido-
mimetic ligands, and a large number of such ligands have
been developed that target tumor-associated integrin hetero-
dimers with high affinity and specificity and show potential as
The interaction of a small library of cyclic DKP–RGD peptidomi-
metics with a5b1 integrin has been investigated by means of
an integrated experimental and computational approach. Bio-
affinity NMR techniques, including saturation transfer differ-
ence (STD) and transferred NOESY, were applied to the ligands
in a suspension of intact MDA-MB-231 breast cancer cells, in
which integrin a5b1 is highly expressed. The NMR data were
compared with the docking calculations of the RGD ligands in
the crystal structure of the a5b1 binding site, and were inte-
grated with competitive binding assays to the purified a5b1 in-
tegrin. Ligand binding epitopes involve protons of both the
RGD moiety and the DKP scaffold, although the stereochemis-
try and the functionalization of the DKP scaffold as well as the
macrocycle conformation determine a great variability in the
interaction. The ligand showing the highest number of STD
signals is also the most potent a5b1 ligand of the series, dis-
playing a nanomolar IC50 value.
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both antitumor and anti-angiogenic agents.[3,5, 6] Among them,
the cyclic pentapeptide cyclo[RGDf(N-Me)V] 1a (developed by
Kessler and known as Cilengitide, Figure 1) has recently failed
a Phase III clinical trial for the treatment of glioblastoma and is
currently undergoing other Phase II clinical trials for the treat-
ment of several cancer types, administered either alone or in
combination with other therapeutic agents.[5, 7]
In this context, we have recently reported a small library of
cyclic RGD peptidomimetic integrin ligands, containing diketo-
piperazine (DKP) scaffolds, as dipeptide mimics capable of con-
trolling the conformation of the tripeptide recognition motif,
as well as differing in the configuration of the two DKP stereo-
centers and in the substitution at the DKP nitrogen atoms.[8] In
particular, the RGD peptidomimetics 2–7 (Figure 1) derived
from trans-DKP scaffolds (DKP2-DKP7) inhibited the binding of
biotinylated vitronectin to aVb3 integrin with low nanomolar
IC50 values. The molecular basis of this activity was rationalized
in terms of preferred ligand conformations featuring an ex-
tended arrangement of the RGD sequence, which are highly
pre-organized for the interaction with integrin aVb3, as demon-
strated by docking studies and NMR experiments with aVb3-
rich bladder cancer cells.[9]
Prompted by these results and by the perspective of target-
ing two key players in angiogenesis and cancer in the RGD-
binding integrin subfamily, we planned to investigate the inter-
action of our cyclic RGD peptidomimetics with a5b1 integrin by
exploiting the same integrated computational and experimen-
tal approach applied in the study of aVb3 integrin.
Recently reported X-ray structures of different a5b1 integrin
headpiece fragments, both in the absence and presence of
linear or cyclic RGD ligands, provide an important starting
point for developing an understanding of the interaction with
small-molecule ligands.[10] Despite some differences in the
overall a5b1 headpiece structure, the cyclic peptide RGD
moiety adopted a bound extended conformation very similar
to the linear RGD peptides and to the cyclic pentapeptide 1a
(Cilengitide)-bound to aVb3 integrin.
[11] Indeed, the X-ray struc-
tures of aVb3 and a5b1 complexed with RGD ligands reveal an
identical atomic basis for the interaction: RGD binds at the
junction of the a and b subunits, the Arg residue fitting into
a cleft in the a subunit, and the Asp coordinating a cation in
the b subunit. In particular, the RGD tripeptide adopts a highly
extended conformation (displaying a distance of about 9 a be-
tween the Cb atoms of Asp and Arg) across the aVb3 and a5b1
integrin subunit interface with the carboxylic and guanidine
groups acting as an electrostatic clamp, respectively, on a posi-
tively charged metal ion of the b subunit (MIDAS) and on sev-
eral a subunit specific acid residues.
The properties of integrins embedded into cell membranes
differ from those of purified receptors, so a pure in vitro or in
silico system may not fully recapitulate the complexity of in-
tegrin-mediated recognition. In this regard, NMR spectroscopy
is a powerful tool for the study of small molecule–biomolecule
complexes.[12] In addition, bioaffinity NMR experiments can be
conducted on small ligands directly in the presence of intact
cells, allowing for a detailed investigation into the binding pro-
cess very close to physiological conditions.[9,13]
Accordingly, to identify the molecular details of the interac-
tion of our cyclic RGD peptidomimetics with a5b1 integrin, we
applied bioaffinity NMR techniques, including saturation trans-
fer difference (STD) and transferred NOESY (tr-NOESY), to li-
gands in a suspension of MDA-MB-231 breast cancer cells, in
which integrin a5b1 is highly expressed. The NMR data were in-
tegrated with the docking calculations of the RGD ligands in
the crystal structure of the a5b1 binding site, thus affording an
improved understanding of ligand–integrin interactions.
Herein, we report a full account of our investigations that have
been completed with competitive binding assays to the puri-
fied a5b1 receptor.
2. Results and Discussion
2.1. Integrin Receptor Competitive Binding Assays
The cyclic RGD peptidomimetics 2–7 were examined in vitro
for their ability to compete with biotinylated fibronectin for
binding to the purified a5b1 receptor. Screening assays were
performed by incubating the immobilized integrin receptor
with various concentrations (10@12–10@4m) of the RGD ligands
in the presence of biotinylated fibronectin (1 mgml@1), and
measuring the bound fibronectin in the presence of the com-
petitive ligands. The ability of the peptidomimetics 2–7 to in-
hibit the binding of biotinylated fibronectin to a5b1 integrin
(expressed as the ligand concentration required for 50% inhibi-
tion) was compared with that of reference compounds 1a (Cil-
engitide) and 1b [cyclo(RGDfV), Figure 1] and with the corre-
Figure 1. Cyclic pentapeptides 1a and 1b and cyclic RGD peptidomimetics
2–7 containing DKP scaffolds.
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sponding IC50 value found for inhibition of biotinylated vitro-
nectin binding to avb3 integrin (Table 1).
All of the ligands showed binding affinities for a5b1 lower
than those for avb3, displaying a selectivity ratio (IC50 a5b1/IC50
avb3) ranging from about 35 (compound 6) to approximately
500 (compound 2). The reference compounds 1a and 1b con-
firmed this trend, exhibiting binding affinities for a5b1 about
25–50 times lower than those for avb3. One potential explana-
tion for this behavior (vide infra) might be the differences be-
tween the binding sites of the two receptor subtypes that can
weaken the electrostatic clamp and other specific interactions.
Among the peptidomimetics tested, compound 7 showed the
highest affinity toward a5b1 integrin, inhibiting the binding of
biotinylated fibronectin to a5b1 with an IC50 value of 25.7 nm.
Interestingly, this ligand was also the most potent avb3 ligand
of the series, displaying a sub-nanomolar IC50 value. Compared
to the corresponding avb3 binding affinities, the a5b1 IC50
values showed a more pronounced dependence on the struc-
ture of the DKP scaffold, ranging from nanomolar to micromo-
lar concentrations.
2.2. Docking Models of a5b1 Integrin
Computational models for the interaction of RGD peptidomi-
metic ligands 2–7 with the a5b1 integrin were built by means
of docking calculations using the Glide program (version 5.7)
of the Schrodinger suite.[14] Two models were developed (see
the Experimental Section for details), one starting from the X-
ray structure of a five-domain a5b1 headpiece fragment bound
to the allosteric anti-b1 inhibitory antibody SG/19 and in com-
plex with a linear RGD peptide (3VI4.pdb),[10b] and the other
one using the most recent high-resolution crystal structure of
a four-domain a5b1 headpiece fragment in complex with the
disulfide-bonded cyclic peptide ACRGDGWCG (4WK4.pdb).[10a]
As noted by the authors of Ref. [10a] , the overall a5b1 head-
piece structure is very similar in both complexes and approxi-
mated to an integrin state that is intermediate between closed
(low affinity) and open (high affinity). Moreover, the cyclic pep-
tide RGD moiety adopts a bound conformation and a binding
mode very similar to those of the linear RGD peptide. In both
X-ray complexes, the RGD motif binds at the junction of the a5
and b1 subunits, adopting a highly extended conformation
across the integrin subunit interface. The Arg and Asp side
chains extend in opposite directions, acting as an electrostatic
clamp and interacting with the negatively charged Asp227
side chain of a5 subunit and the b1 MIDAS cation, respectively.
Further stabilizing hydrogen bonds occur between the ligand
Arg guanidine group and a5 Gln221 side chain, the ligand Asp
carboxylic group and b1 Asn224, Tyr133 backbone amide and
Ser132 side chain, and between the ligand Asp backbone
amide and the backbone carbonyl of b1 Leu225. In addition,
the cyclic peptide Trp side chain forms a T-shaped interaction
with the a5 Trp157 side chain.
Although the RGD binding mode found in a5b1 integrin re-
capitulates the RGD interaction with b3 integrins, differences
between a5b1 and aVb3 integrin binding pockets can affect the
ligand recognition, as shown by competitive binding assays
(Table 1). For instance, the mutation of aV Asp150 into a5
Ala159 produces a less acidic region, whereas the mutation of
Arg214 and Arg216 (b3) into the hydrophobic residues Gly223
and Leu225 (b1) both expands the site and reduces the polar
character of the region. Owing to the different physicochemi-
cal features of binding sites, the ligands could interact less
strongly with a5b1 and reveal a greater mobility within this re-
ceptor site compared to aVb3.
In all of the calculations, the X-ray binding mode of the RGD
motif with the a5b1 integrin was taken as a reference model
for the analysis of the docking results in terms of ligand–pro-
tein interactions (see Figure S1). According to the similarity be-
tween the crystal structures of a5b1 (3VI4 and 4WK4), compara-
ble results for the docking of ligands 2–7 in the two a5b1 in-
tegrin models were obtained.
2.3. NMR Analysis
The molecular details of the interaction between our cyclic
RGD peptidomimetics and a5b1 integrin were investigated by
applying bioaffinity NMR techniques to the ligands in a suspen-
sion of intact MDA-MB-231 breast cancer cells, in which the in-
tegrin a5b1 is highly expressed (a5b1/aVb3 expression ratio=
7.1, ratio of mean fluorescence intensity determined by flow
cytometry).[15]
The NMR analysis of the interaction was performed by satu-
ration transfer difference (STD) and transferred NOESY (tr-
NOESY) that focus on the NMR signals of the ligand and utilize
NOE effects between the protein and the ligand. In particular,
STD experiments permitted the identification of the epitope,
pinpointing the interaction between parts of each ligand and
the receptor, whereas tr-NOESY data provided information on
the bioactive conformation.
The conformation of ligands 2–7 in the presence of intact
MDA-MB-231 cells was detected by tr-NOESY experiments per-
formed at 283 K in non-deuterated phosphate buffer at pH 7.2.
Under these experimental conditions, compounds 3, 4, 5, and
7 confirmed the free-state conformational behavior (summar-
Table 1. Inhibition of biotinylated fibronectin binding to a5b1 integrin
compared with inhibition of biotinylated vitronectin binding to avb3.
Compound IC50 [nM]
[a]
a5b1
IC50 [nM]
[b]
avb3
IC50 [a5b1]/IC50 (avb3)
2 1647:871 3.2:2.7 515
3 532:35 4.5:1.1 118
4 314:1.4 7.6:4.3 41
5 1217:157 12.2:5.0 100
6 73.3:3.7 2.1:0.6 35
7 25.7:6.2 0.2:0.09 128
1a 14.4:3.1 0.6:0.1 24
1b 166:28 3.2:1.3 52
[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of biotinylated fibronectin binding as estimated
by GraphPad Prism software; all values are the arithmetic mean:SD of
triplicate determinations. [b] Calculated as the concentration of com-
pound required for 50% inhibition of biotinylated vitronectin binding.
See Ref. [7a] for 1a and Ref. [8c] for 1b and 2–7.
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ized in the Supporting Information),[8c] displaying NOE contacts
in the bound state very similar to those in the free state. In
particular, ligands 3 and 5 show, in the respective tr-NOESY
spectra, a cross peak between NHArg@NHGly, which is indicative
of a pseudo-b-turn motif at DKP–Arg stabilized by a hydrogen
bond between NHGly and C(5)=O (referred to as a type III H-
bonding pattern,[16] Figure 2).
Also, the conformation of ligand 2 in the presence of the
cell suspension can be re-conducted to the type III geometry
observed in the free state, although the significant NOE con-
tact is absent in the tr-NOESY spectrum. Indeed, the similarity
of all other NOE contacts in the free and bound state does not
suggest significant differences between the corresponding
conformations.
Conversely, ligands 4, 6, and 7 were shown in the free state
to adopt a conformation characterized by a b-turn motif at
Gly–Asp stabilized by a hydrogen bond between DKP@NH10
and Arg@C=O (referred to as a type I H-bonding pattern,
Figure 3),[16] and by the NH10@NHAsp NOE contact (at least in
compounds 6 and 7). Their tr-NOESY spectra revealed high
similarity to the free-state spectra, confirming the presence of
the type I conformation in the interaction with a5b1 integrin.
Interestingly, only the cross peak NH10@NHAsp is evident in the
tr-NOESY spectrum of compound 6 (Figure 3), suggesting the
selection of the type I conformation in the bound state be-
tween the two main geometries detected in the free state (de-
scribed in the Supporting Information).[8c] Remarkably, the li-
gands adopting the type I conformation in the bound state
(compounds 4, 6 and 7) showed the best binding affinities to
the a5b1 receptor among the cyclic RGD peptidomimetics
(lowest IC50 values in Table 1).
To provide information, at atomic level, on the ligand inter-
actions with protein residues, one-dimensional STD experi-
ments of the compounds 2–7 in the presence of MDA-MB-231
cell suspension were performed. As control experiments, the
STD spectra of a RGD ligand without cells and of a non-RGD
compound (e.g. mannose) in the presence of cells were record-
ed. In both cases, no signals were observed. The protons of
compounds 2–7, which exhibit a signal in the STD spectra and
Figure 2. A) Type III H-bonding pattern (pseudo-b-turn at DKP–Arg) pro-
posed for compound 3 on the basis of spectroscopic data. The arrow indi-
cates the NHArg@NHGly NOE contact and the dotted line represents the intra-
molecular hydrogen bond. B) tr-NOESY spectrum (NH region) of com-
pound 3 in MDA-MB-231 cancer cell suspension. The cross peaks are relative
to the NHArg@NHGly interaction.
Figure 3. A) Type I H-bonding pattern (b-turn at Gly–Asp) proposed for com-
pound 6 on the basis of spectroscopic data. The arrow indicates the NH10@
NHAsp NOE contact and the dotted line represents the intramolecular hydro-
gen bond. B) tr-NOESY spectrum (NH region) of compound 6 in MDA-MB-
231 cancer cell suspension. The cross peak is relative to the NH10@NHAsp
interaction.
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hence interact with the integrin receptor site, are marked with
a full circle in Figure 4.
This scheme highlights how all compounds have points of
contact with the a5b1 receptor. Transfer signals generally re-
quire a distance from the receptor of less than 5 a, and the
smaller the distance compared with other residues in the
ligand, the stronger the transfer signal. Therefore, the degree
of saturation of individual ligand protons (expressed as abso-
lute-STD percent) reflects their proximity to the target surface.
The absolute STD values of all ligands (see Table S7 of the Sup-
porting Information) can be compared by considering the simi-
lar nature of the compounds, the equivalence in concentration
and in the ratio ligand to protein of the samples. To facilitate
the interpretation of NMR data, absolute STD percent values
are transformed into relative STD% values (see Table S7) for
each molecule on the basis of the strongest signal. The relative
STD% are grouped into five intensity ranges, as shown in
Figure 4 (black=100%, green>70%, 50< red<70%, 30<
orange<50%, yellow<30%).
A first analysis of the STD data indicates the great variability
of the interactions: each ligand binds the receptor site with
a different epitope. Indeed, the STD spectra of ligands 2–7 in
the presence of cells differ for the number and intensity of the
signals and for the type of protons involved in the interaction.
This behavior underlines how the ligand stereochemistry and
functionalization at the DKP nitrogen atoms are decisive in the
formation of the ligand–protein complex. The CH2–benzylic
protons and DKP–H6 are not evaluated, because their chemical
shifts are very close to the water signal.
However, all of the ligands share some common binding fea-
tures: the aromatic and the guanidinic protons are in contact
with the receptor, although with different STD percentages.
Overall, within the RGD motif, the arginine residue displays
a higher transfer signal than the aspartate residue, presumably
because the aspartate interaction with the receptor is mediat-
ed by the coordination to a metal cation and, thus, compared
with arginine, the aspartate protons could be more distant
from the integrin. The STD NMR data were interpreted with
the aid of docking calculations in the crystal structure of the
a5b1 binding site and an integrated discussion is reported
below for each ligand.
2.4. Ligands Adopting the Type I Bound Conformation
The STD spectrum of ligand 7 in the presence of MDA-MB-231
cell suspension is shown in Figure 5.
With respect to the other library compounds, this ligand
shows the highest number of protons involved in the interac-
tion with an intensity greater than 50% of relative STD. The
largest STD effects (greater than 70% of relative STD) are ob-
served for DKP–H9, DKP–H3 (protons of the scaffold) and the
Figure 4. Relative STD% values, grouped in five intensity ranges for ligands 2–7 interacting with MDA-MB-231 cells (black=100%, green>70%,
50< red<70%, 30<orange<50%, yellow<30%).
Figure 5. NMR spectra of compound 7. A) Low field and C) high field signifi-
cant regions of the STD–NMR spectrum. B–D) The same regions of the
1H NMR spectrum.
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protons of the two aromatic groups (Figure 4, black and green
balls). Other protons appear in the spectrum with a relative
STD between 50 and 70%: DKP–H7, NH10, and HaGly (Figure 4,
red balls). Additionally, the signals of NHGly and NHAsp overlap
and it is difficult to assess their involvement in the binding
process. Overall, the interaction of 7 with the receptor site is
strong and involves protons of both the RGD moiety and the
DKP scaffold. Indeed, this compound appears to be the most
potent ligand of the series by effectively inhibiting the binding
of biotinylated fibronectin to the isolated a5b1 integrin at
nanomolar concentration (IC50=25.7:6.2 nm). Docking calcu-
lations starting from the type I bound conformation of com-
pound 7 produced top-ranked binding modes, conserving all
the key interactions described for the RGD peptides in the X-
ray complexes (Figure 6a).
In addition to the interactions of ligand guanidinium group
with a5 Asp227 (side-on) and Gln221 (head-on) side chains,
and to the interactions of ligand carboxylate moiety with
MIDAS and b1 Asn224, Tyr133, Ser134 backbone amides, fur-
ther stabilizing H bonds occur between the ligand Asp back-
bone amide and the carbonyl of b1 Leu225, and between the
ligand Gly backbone carbonyl and the b1 Ser227 side chain.
Moreover, in agreement with the STD data, the two benzyl
groups are in contact with b1 subunit residues, one interacting
with the aromatic side chain of Tyr133 and the other one
pointing towards ADMIDAS ion and some surrounding resi-
dues (Ser134, Asp259, Ala342), and the protons DKP–H3 and
DKP–H9 of the scaffold are close to the b1 Ser134 residue.
Compounds 4 and 6 feature the same benzyl substitution at
the endocyclic nitrogen N-1 of the scaffold and the opposite
configuration of the two DKP stereocenters (see Figure 4). Ac-
cordingly, the two side arms of the diketopiperazine scaffold
show a different stereochemical orientation that could affect
the interaction of the ligands with the a5b1 receptor site. In
fact, even though, for both ligands, the largest STD effect in-
volves the aromatic protons (100% relative STD), the STD spec-
tra of 4 and 6 show some differences in intensity and assign-
ment of the signals. Similarly to ligand 7, the STD spectrum of
compound 6 includes protons belonging to both the scaffold
and the RGD moiety: NH4, DKP–H9, HaGly, and the guanidine
NH protons show comparable and notable STD intensities (48–
63% relative STD, see Table S7 of the Supporting Information)
and, consequently, as the aromatic protons, can be considered
lying close to the protein surface. This analysis nicely agrees
with the ability of ligand 6 to inhibit the binding of biotinylat-
ed fibronectin to the isolated a5b1 integrin at nanomolar con-
centration (IC50=73.3:3.7 nm). In agreement with the STD
data and similarly to compound 7, docking calculations show
that compound 6 binds to the a5b1 receptor with the Asp car-
boxylate group coordinating the metal ion at the MIDAS and
interacting with b1 Asn224, Tyr133, Ser134 backbone amides,
and the Arg guanidinium moiety establishing a bidentate salt
bridge with a5 Asp227 and a H bond with a5 Gln221 (Fig-
ure 6b). Moreover, the benzyl moiety is in proximity to b1
Ser227 and a5 Ser224, confirming the importance of the inter-
action of the aromatic group with the integrin binding pocket,
whereas HaGly is in contact with the a5 Phe187 side chain, and
protons NH4 and DKP–H9 of the scaffold are close to the b1
Ser134 residue. It is worth noting that, compared to ligand 7,
compound 6 orientates the scaffold and the aromatic ring
toward a different region of the receptor site (Figure 6). This
binding mode affects the interaction of the whole ligand with
the receptor and, as a consequence, could explain the lack of
STD signals for some protons.
The STD spectrum of compound 4 includes protons belong-
ing to the DKP scaffold, the benzyl group, and the Arg residue,
suggesting the close proximity of these moieties to the integ-
rin surface. Compared to 6, we observe a significant enhance-
ment of STD intensity for DKP–H7, the appearance of impor-
tant signals for DKP–H3 and NHArg, and the disappearance of
the HaGly contact. Docking calculations show that compound 4
can fit into the a5b1 receptor pocket with different energetical-
ly favorable orientations, mainly differing in the position of the
aromatic group and, consequently, of the DKP scaffold and the
cyclic peptide backbone (see Figure S5). The mobility of the
ligand within the a5b1 binding site revealed by docking poses
is likely responsible of the non-optimal interaction pattern ob-
served for the RGD sequence with the MDA-MB-231 cells and
Figure 6. Docking best poses of a) compound 7 (green) and b) com-
pound 6 (green) in the crystal structure of the extracellular domain of a5b1
integrin (a5 subunit pink, b1 subunit cyan, model from 3VI4.pdb). Only se-
lected integrin residues involved in interactions with the ligand are shown.
Non polar hydrogens are hidden for clarity, whereas intermolecular hydro-
gen bonds are shown as dashed lines.
ChemistryOpen 2017, 6, 128 – 136 www.chemistryopen.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim133
of the sub-micromolar affinity for the a5b1 receptor (IC50 314:
1.4 nm).
In conclusion, for type I ligands 4, 6, and 7, the aromatic
groups display the major STD intensity. Moreover, the interac-
tion between the guanidinium group and the integrin is pres-
ent in all the compounds, whereas the RGD backbone and
DKP scaffold protons contribute differently to the ligand
epitope.
2.5. Ligands Adopting the Type III Bound Conformation
The ligands adopting the type III conformation in the bound
state (compounds 2, 3, and 5) showed the lowest binding af-
finities to the a5b1 receptor among the cyclic RGD peptidomi-
metics tested (highest IC50 values in Table 1, ranging from
532:35 nm of 3 to 1647:871 nm of 2). Nevertheless, clear
peaks caused by magnetization transfer were observed in their
STD spectra, revealing different binding epitopes to a5b1-rich
cancer cells, which share the aromatic and the guanidinic pro-
tons, even though with variable intensities. In particular, the
STD spectrum of compound 2 (displaying the greatest variabili-
ty in the competitive binding assay and the worst a5b1 IC50)
shows many signals of low intensity, relative to protons of
both the scaffold and the RGD moiety, and only one signal
(NHGuan) displaying an absolute STD percentage higher than
1% (Table S7 of the Supporting Information). This behavior
suggests that the most important recognition takes place by
means of the guanidinium group (100% relative STD) and that
the cyclopeptide conformation of ligand 2 combined with its
DKP configuration does not likely allow a favorable interaction
of the other protons (e.g. the aromatic protons) with a5 or b1
residues. On the contrary, the STD spectra of ligands 3 and 5
show 100% relative STD effects for the aromatic protons, indi-
cating their close proximity to the integrin surface. Relative
STD% values of notable intensity are displayed also by guani-
dine and scaffold protons of these ligands, supporting their
ability to interact with a5b1-rich cancer cells.
Docking calculations starting from the type III conformation
into the a5b1 model generated ligand binding modes that
could explain the poor ability of compounds 2, 3, and 5 to
compete with biotinylated fibronectin for the binding to the
purified a5b1 integrin, while maintaining extended conforma-
tions and several interactions with the receptor site. In fact,
docking results starting from type III conformations showed
both the classical RGD interaction pattern observed in X-ray
complexes as well as alternative binding modes lacking the
classical electrostatic clamp. This behavior is well exemplified
by docking poses of ligand 3, which adopts two main binding
modes within the a5b1 receptor site (Figure 7). In the best
pose, representing binding mode A (Figure 7a), ligand 3 forms
all the key crystallographic interactions, where the benzyl
group is in contact with the side chains of b1 Tyr133, Ser134,
Asp259 and Glu320, and the NH10 proton is close to the b1
Ser134 residue. In the alternative binding mode B (Figure 7b),
at less favorable docking scores, the guanidinium group loses
the electrostatic interaction with the a5 Asp227 side chain and
forms a cation-p interaction with the a5 Trp157 aromatic ring
and a salt bridge with the a5 Glu126 side chain, whereas the
benzyl group interacts with the a5 Phe187 side chain and the
NH1 and NH10 protons are close to b1 Tyr133 and Ser134 resi-
dues, respectively.
The two binding modes can be used to interpret NMR re-
sults with MDA-MB-231 cells, suggesting that both the ligand
arrangements in the binding pocket could contribute to the
experimental binding epitope. The possibility of adopting dif-
ferent binding modes within the a5b1 receptor site, owing to
the specific features of the pocket, could decrease the ligand
ability to compete with biotinylated fibronectin in the binding
assay, thus explaining the low affinity for the isolated receptor.
3. Conclusions
In our current work, we planned to investigate the interaction
of cyclic RGD–DKP peptidomimetic ligands 2–7 with a5b1 in-
tegrin by exploiting an integrated computational and experi-
Figure 7. Docking binding modes: a) A and b) B of compound 3 (green) in
the crystal structure of the extracellular domain of a5b1 integrin (a5 subunit
pink, b1 subunit cyan, model from 3VI4.pdb). Only selected integrin residues
involved in interactions with the ligand are shown. Non polar hydrogens are
hidden for clarity, whereas intermolecular hydrogen bonds are shown as
dashed lines.
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mental approach. Our ligands, designed to target the avb3 in-
tegrin, adopt an extended conformation of the RGD moiety,
appropriate also to interact usefully with the receptor site of
a5b1 integrin. We use NMR methodologies based on the Over-
hauser effect: STD and transferred NOESY, to study the ligand–
protein interactions. The NMR experiments were performed on
a suspension of intact MDA-MB-231 breast cancer cells where
the a5b1 integrin is overexpressed, allowing for a detailed in-
vestigation of the binding process very close to physiological
conditions. The NMR results were supported by docking calcu-
lations and were compared with competitive binding assays to
the purified a5b1 integrin.
The conformational analysis of the bound ligands revealed
that the bioactive conformations of the ligands can be repre-
sented with two well-defined preferred geometries : type I and
type III. Remarkably, the ligands adopting the type I conforma-
tion in the bound state (compounds 4, 6, and 7) showed the
best binding affinities to the a5b1 receptor. The results ob-
tained from STD–NMR experiments are in agreement with
docking analysis, pinpointing how the ligand stereochemistry
and functionalization at the DKP nitrogen atoms are decisive
in the formation of the ligand–protein complex. In any case,
the aromatic moieties as well as the guanidinic protons are in
contact with the receptor, although with different STD percen-
tages for each ligand. The best ligand of our library is com-
pound 7 [IC50=25.7:6.2 nm] that produced top-ranked bind-
ing modes conserving all the key interactions described for the
RGD peptides in the X-ray complexes. Nevertheless, mimic 7
exhibits a binding affinity for a5b1 about 100 times lower than
that for avb3. This behavior was observed for all compounds of
the library and might be imputed to the features of the a5b1
receptor site. In conclusion, the combination of advanced NMR
techniques and computational modeling permitted us to iden-
tify structural requirements necessary to obtain an effective
ligand.
Experimental Section
Competitive Binding Assays
Purified recombinant human integrin a5b1 (R&D Systems, Inc. , Min-
neapolis, MN, USA) was diluted to 0.5 mgmL@1 in coating buffer
containing 20 mm Tris-HCl (pH 7.4), 150 mm NaCl, 1 mm MnCl2,
2 mm CaCl2, and 1 mm MgCl2. Diluted receptor (100 mL/well) was
added to 96-well microtiter plates (NUNC MW 96F Maxisorp
Straight) and incubated overnight at 4 8C. The plates were then in-
cubated with blocking solution [coating buffer plus 1% bovine
serum albumin (Sigma, St. Luis MO, USA)] for an additional 2 h at
room temperature to block nonspecific binding, followed by 3 h
incubation at room temperature with various concentrations
(10@12-–10@4m) of test compounds in the presence of 1 mgmL@1
biotinylated fibronectin (Sigma, St. Luis MO, USA). Biotinylation
was performed by using an EZ-Link Sulfo-NHS-Biotinylation kit
(Pierce, Rockford, IL, USA). After washing, the plates were incubat-
ed for 1 h at room temperature with streptavidin-biotinylated
hourseradish peroxidase complex (Amersham Biosciences, Uppsala,
Sweden) followed by 30 min incubation with 100 mL/well substrate
reagent solution (R&D Systems, Minneapolis, MN, USA) before stop-
ping the reaction by addition of 50 mL/well 2N H2SO4. The absorb-
ance at 415 nm was read in a SynergyTM HT multi-detection mi-
croplate reader (BioTek Instruments, Inc.). Each data point repre-
sents the average of triplicate wells; data analysis was carried out
by nonlinear regression analysis with Prism GraphPad program.
Computational Studies
Protein Setup
Two crystal structures of the extracellular domain of the integrin
a5b1 in a complex with linear and cyclic RGD peptides (PDB code:
3VI4 and 4WK4, respectively) were used for docking studies. Dock-
ing was performed only on the globular head of the integrin, be-
cause the headgroup of integrin has been identified in the X-ray
structure as the ligand-binding region. The two protein structures
were set up for docking as follows: the protein with the linear RGD
ligand was truncated to residue sequences 40–351 for chain
a (chain A of crystal asymmetric unit) and 121–358 for chain
b (chain B of crystal asymmetric unit). All water was deleted. Ac-
cording to X-ray structures, metal cations at MIDAS have been
modeled as Mg2+ ions, whereas all the other metal cations were
modeled as Ca2+ ions. As the complex of integrin a5b1 bound to
the linear RGD peptide, that is, 3VI4.pdb, lacks the metal ion of AD-
MIDAS (adjacent to MIDAS, metal ion-dependent adhesion site), it
was added according to the apo structure of integrin (3VI3.pdb)
and to the cyclic RGD peptide crystallographic complex
(4WK4.pdb). The two structures were then prepared by using the
Protein Preparation Wizard of the graphical user interface Maestro
and the OPLSAA force field. Hydrogen bonds were optimized ac-
cording to the exhaustive sampling option and the entire com-
plexes were optimized by using a restrained minimization with
convergence on heavy atoms to a RMSD (root-mean-square devia-
tion) of 0.30 a.
Ligand Docking Calculations
The automated docking calculations were performed by using
Glide version 5.7 in the standard precision (SP) mode.[14] The grids
were generated for the RGD–integrin a5b1 complexes structure
prepared as described in the protein setup section. The center of
the grid-enclosing box was defined by the center of the bound
ligand. The enclosing box dimensions, which are automatically de-
duced from the ligand size, fit the entire active site. For the dock-
ing step, the size of the inner box for placing the ligand center
was set to 12 a. No further modifications were applied to the de-
fault settings. The GlideScore function was used to select 10 poses
for each ligand. To validate the docking protocol, a high-affinity
ligand was selected, that is, the cyclic pentapeptide Cilengitide 1a,
showing an IC50 value to isolated receptor of 14.4 nm (see Table 1).
The program was successful in reproducing the experimentally de-
termined binding mode of RGD peptides, as it corresponds to the
best-scored pose in both docking models (see Figure S1).
NMR Studies
All NMR spectra were registered at 283 and 298 K by using 7–
9 mm solutions of the test compounds in saline phosphate buffer
(pH 7.2) and containing 10% D2O. The NMR assignment of the
compounds were performed through one- and two-dimensional 1H
and 13C NMR spectra. The proton resonances did not show signifi-
cant shifts when the compound was analyzed in the presence of
the cells suspension. For conformational analysis, NOESY with
700 ms and tr-NOESY with 200 ms of mixing time were used. The
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STD–NMR spectra were acquired in the presence of about 106
MDA-MB-231 cells in a total volume of 200 mL, using the watergate
sequence for water suppression. The STD experiments discussed
herein were achieved at 283 K by using a total irradiation time of
2.94 s. All negative controls were performed: unwanted STD signals
were not observed in any of the spectra.
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